What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study, Pre-Registered Trial).

What question did this study set out to answer?

This research aims to evaluate the safety and efficacy of a novel bispecific CAR-T therapy targeting BCMA and CD19 in refractory autoimmune diseases.

December 8, 2025BloodOpen Access

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

View Full Paper

Ask AI

Bookmark

Authors

JPJing Pan AZAng Zhang SLSha Li

Discussion

Member takes

Overview

Pilot study demonstrates safety and preliminary efficacy of bispecific CAR-T therapy in systemic lupus erythematosus and systemic sclerosis patients, suggesting a promising treatment approach.

Key Points

This research aims to evaluate the safety and efficacy of a novel bispecific CAR-T therapy targeting BCMA and CD19 in refractory autoimmune diseases.
Developed a bispecific CAR structure using proprietary nanobodies.
Conducted a pilot study evaluating safety and efficacy in patients with systemic lupus erythematosus, systemic sclerosis, and primary Sjögren's syndrome.
Measured clinical outcomes using established criteria like SLEDAI, LLDAS, SRI-4, EUSTAR-AI, and ESSDAI.
Among 12 treated patients, the overall response rate for systemic lupus erythematosus was 83.3%, with 4 achieving complete remission.
All systemic sclerosis patients showed positive response rates at 1 month, with significant reductions in modified Rodnan scores.
Safety outcomes indicated low incidence of CRS and no severe adverse events.

Cite This Study

Pan et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddb2 https://doi.org/10.1182/blood-2025-2370

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

View Full Paper

Ask AI

Bookmark

Authors

JPJing Pan AZAng Zhang SLSha Li

Discussion

Member takes

Overview

Pilot study demonstrates safety and preliminary efficacy of bispecific CAR-T therapy in systemic lupus erythematosus and systemic sclerosis patients, suggesting a promising treatment approach.

Key Points

This research aims to evaluate the safety and efficacy of a novel bispecific CAR-T therapy targeting BCMA and CD19 in refractory autoimmune diseases.
Developed a bispecific CAR structure using proprietary nanobodies.
Conducted a pilot study evaluating safety and efficacy in patients with systemic lupus erythematosus, systemic sclerosis, and primary Sjögren's syndrome.
Measured clinical outcomes using established criteria like SLEDAI, LLDAS, SRI-4, EUSTAR-AI, and ESSDAI.
Among 12 treated patients, the overall response rate for systemic lupus erythematosus was 83.3%, with 4 achieving complete remission.
All systemic sclerosis patients showed positive response rates at 1 month, with significant reductions in modified Rodnan scores.
Safety outcomes indicated low incidence of CRS and no severe adverse events.

Cite This Study

Pan et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddb2 https://doi.org/10.1182/blood-2025-2370

View Full Paper

Ask AI

Bookmark